TolerogenixX

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I clinical trial, the technique was successfully employed during kidney transplants. Patients who received transplants became tolerant of the donated organ. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance thi